These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11769820)

  • 1. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England.
    Biswasl PN; Wilton LV; Pearcel GL; Freemantle S; Shakir SA
    J Psychopharmacol; 2001 Dec; 15(4):265-71. PubMed ID: 11769820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    J Psychopharmacol; 2007 Jun; 21(4):392-9. PubMed ID: 17656426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of development on olanzapine-associated adverse events.
    Woods SW; Martin A; Spector SG; McGlashan TH
    J Am Acad Child Adolesc Psychiatry; 2002 Dec; 41(12):1439-46. PubMed ID: 12447030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England.
    Biswas PN; Wilton LV; Shakir SA
    J Psychopharmacol; 2003 Mar; 17(1):121-6. PubMed ID: 12680749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN; Wilton LV; Shakir SW
    J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
    Wilton LV; Heeley EL; Pickering RM; Shakir SA
    J Psychopharmacol; 2001 Jun; 15(2):120-6. PubMed ID: 11448085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine.
    Hale AS
    Br J Hosp Med; 1997 Nov 5-18; 58(9):442-5. PubMed ID: 9619205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events related to olanzapine.
    Conley RR; Meltzer HY
    J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe akathisia during olanzapine treatment of acute schizophrenia.
    Jauss M; Schröder J; Pantel J; Bachmann S; Gerdsen I; Mundt C
    Pharmacopsychiatry; 1998 Jul; 31(4):146-8. PubMed ID: 9754850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
    Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
    Layton D; Harris S; Wilton LV; Shakir SA
    J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
    Marshall V; Wilton L; Shakir S
    Acta Diabetol; 2006 May; 43(1):6-13. PubMed ID: 16710643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.
    Marder SR; Sorsaburu S; Dunayevich E; Karagianis JL; Dawe IC; Falk DM; Dellva MA; Carlson JL; Cavazzoni PA; Baker RW
    J Clin Psychiatry; 2010 Apr; 71(4):433-41. PubMed ID: 20156413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.